|Find A PhysicianHome | Library | myDownstate | Newsroom | A-Z Guide | E-mail | Contact Us | Directions|
Research Activities and Grants
Vaysman D, Davis JM, Rosenfeld W, Pollack S, Pucch P, Lee HS: Respiratory morbidity and pulmonary function in 5-6 year old children born prematurely and treated with recombinant human CuZn superoxide dismutase (Internet J of Pediatrics and Neonatology - in press)
Veloira WG, Vaysman D, Lee HS: Acute respiratory failure secondary to primary spontaneous pneumothorax. Pediatric Emergency care 22:116-117, 2006.
Vaysman D, Veloira WG, Schuss AL, Lee HS: Idiopathic Pulmonary Hemosiderosis. Pediatric Asthma, Allergy and Immunology 17:151-155, 2004.
Mazzie JP, Price AP, Khullar P, Montoya CH, Roberts JE, Lee HS, Williams L, Schuss A, Katz DS: Radiology-Pathology Conference: Lymphomatoid Granulomatosis in a Pediatric Patient. Clinical Imaging 28:209-213, 2004.
Vaysman D, Davis JM, Rosenfeld W, Pollack S, Pucch P, Lee HS : Respiratory morbidity and pulmonary function in 5-6 year old children born prematurely and treated with intratracheal recombinant human CuZn superoxide dismutase. The Internet J of Pediatrics and Neonatology 7: ISSN 1528-8374, 2007
2006-2009 Lee HS: A phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate a Single Intramuscular Dose of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), for the Outpatient Treatment of Children with RSV Illness. MedImmune. $32, 810
2006-2009 Lee HS : A 52 -weeks, randomised, double-blind, parallel-group, multi-center, phase lllB study comparing the long tem safety of SYMBICORT ® pMDI 160/4.5 ug x 2 actuations twice daily to budesonide HFA 160 ug x 2 actuations twice daily in adult and adolescent (›= 12 years) African American subjects with asthma AstraZeneca $ 100,000
2006-2006 Lee HS : A 1-Year, Randomized, Double-Blind, Parallel-Group, Placebo Controlled,Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Omalizumab in Children ( 6- less than 12 years ) with Moderate Severe, Persistent, Inadequately Controlled Allergic Asthma. Novartis. $ 4,900
2006-2009 Lee HS: A Phase lllb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects With Moderate To Severe Persistent Asthma Who are Inadequately Controlled With High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists. Genentech, Inc. $ 9319/patient (co-investigator)
2005-2006 Lee HS: A Pivotal Phase 3 Study of MEDI-524 (NUMAX TM), an Enhanced Potency Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children. Protocol MI-CP 110. Medimmune. $ 108, 450
2005-2006 Lee HS: A Randomized, 2- Period, Multicenter, Double-Blind, Parallel-Group Study Comaparing the Effects of 2 Doses of Montelukast Granules and Placebo in the Treatment of Respiratory Symptoms Associated with Respiratory Syncytial Virus-Induced Bronchiolitis in Children Aged 3 to 24 Months MK-0476 IND 58,819 Protocol 272-05. Merck $ 15,102
2004 Lee HS: Unrestricted educational grant. Genentech. $15,000
2003-2004 Lee HS: Twelve-Week, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study of SYMBICORT pMDI Administered Once Daily in Children and Adolescents 6 to 15 years of Age with Asthma - SPROUT. AstraZeneca. $5,825
2003-2004 Lee HS: A Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-Center Study of VENTOLIN HFA MDI delivered with facemask and two different holding chambers in Subjects aged 24 to less than 48 months with asthma symptoms (i.e. wheeze, cough, dyspnea or chest tightness ) consistent with bronchospasm or obstructive airway disease. GlaxoSmithKline. $2,000
2003-2004 A Randomized, 2-Period, Multicenter, Double-Blind, Parallel-Group Study Comparing the Effects of 2 Doses of Montelukast Granules and Placebo in the Treatment of Respiratory Symptoms Associated With Respiratory Syncytital Virus-Induced Bronchiolitis in Children Aged 6 to 18 Months. Merck. $4000
2003-2004 Lee HS: A Randomized, Double-Blind, Double- Dummy, Placebo- Controlled, Parallel Group, Multi-Center Clinical Trial of Four Weeks Treatment with SEREVENT Inhalation Aerosol, 25mcg BID, 50mcgBID and Placebo Administered Via a Valved Holding Chamber with Facemask in Subjects with Asthma Age 6 to 23 Months. GlaxoSmithKline. $2,000
2003-2004 Lee HS: A Randomized (2:1), Stratified, Double- Blind, Parallel- Group, Placebo- Controlled, 12-weeks, Multi-Center Trial of Fluticasone Propionate HFA Inhalation Aerosol 88mcg BID versus Placebo HFA Delivered via an MDI and a Valved Holding Chamber with Facemask in Pediatric Subjects 1 to ‹ 4 years with Asthma. GlaxoSmithKline. $6,756.
2002-2003 Lee: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Clinical Trial of Four Weeks Treatment with SEREVENT Inhalation Aerosol, 25mcg BID, 50mcg BID and Placebo administered via a Valved Holding Chamber with Facemask in Subjects with Asthma Age 24 to 47 months. $36,600. 2002-2003 Synagis (palivizumab) Outcomes Registry. Medimmune, Inc. $2700
2001-2002 Lee HS: An Efficacy, Safety and Tolerability Study of Daily Dosing with Levalbuterol, Racemic Albuterol and Placebo in Pediatric Subjects 2-5 years Old with Asthma. Sepracor Inc. 051-032. $46,835 2001RSV Prophylaxis. Medimmune, Inc. $8,500
2001-2002 Lee HS: Synagis (palivizumab) Outcome Registry. Medimmune, Inc. $3,500
2000-2001 Lee HS: Synagis (palivizumab) Outcome Registry. Medimmune, Inc. $2,000